Literature DB >> 23828613

A rare SNP in pre-miR-34a is associated with increased levels of miR-34a in pancreatic beta cells.

Jonathan M Locke1, Hana Lango Allen, Lorna W Harries.   

Abstract

Changes in the levels of specific microRNAs (miRNAs) can reduce glucose-stimulated insulin secretion and increase beta-cell apoptosis, two causes of islet dysfunction and progression to type 2 diabetes. Studies have shown that single nucleotide polymorphisms (SNPs) within miRNA genes can affect their expression. We sought to determine whether miRNAs, with a known role in beta-cell function, possess SNPs within the pre-miRNA structure which can affect their expression. Using published literature and dbSNP, we aimed to identify miRNAs with a role in beta-cell function that also possess SNPs within the region encoding its pre-miRNA. Following transfection of plasmids, encoding the pre-miRNA and each allele of the SNP, miRNA expression was measured. Two rare SNPs located within the pre-miRNA structure of two miRNA genes important to beta-cell function (miR-34a and miR-96) were identified. Transfection of INS-1 and MIN6 cells with plasmids encoding pre-miR-34a and the minor allele of rs72631823 resulted in significantly (p < 0.05) higher miR-34a expression, compared to cells transfected with plasmids encoding the corresponding major allele. Similarly, higher levels were also observed upon transfection of HeLa cells. Transfection of MIN6 cells with plasmids encoding pre-miR-96 and each allele of rs41274239 resulted in no significant differences in miR-96 expression. A rare SNP in pre-miR-34a is associated with increased levels of mature miR-34a. Given that small changes in miR-34a levels have been shown to cause increased levels of beta-cell apoptosis this finding may be of interest to studies looking at determining the effect of rare variants on type 2 diabetes susceptibility.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23828613      PMCID: PMC3969511          DOI: 10.1007/s00592-013-0499-1

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


Introduction

Recent genome-wide association studies (GWAS) have identified common (minor allele frequency (MAF) >5 %) single nucleotide polymorphisms (SNPs) associated with risk of type 2 diabetes [1, 2]. Most of these SNPs seem to exert their effect by affecting beta-cell function, rather than insulin action [3]. However, despite some success, these findings only explain ~10 % of the heritability of type 2 diabetes [1]. It has been widely postulated that rare genetic variation (MAF <1 %) could explain some of the “missing heritability” [4, 5]. MicroRNAs (miRNAs) are single-stranded, non-protein coding RNAs ~21–23 nucleotides in length that regulate gene expression by binding to mRNAs, via complementary base pairing, resulting in mRNA decay and/or translational repression. Recent studies are revealing important roles for specific miRNAs in regulating beta-cell functions, particularly glucose-stimulated insulin secretion and apoptosis (reviewed in [6]). In rodent models, during the progression to diabetes, expression of specific miRNAs has been shown to change, and manipulating the levels of these miRNAs by silencing or mimicry experiments has revealed a causal role in beta-cell dysfunction [7]. Given the need to tightly control the levels of specific miRNAs for correct beta-cell function, we sought to determine whether SNPs present within the precursor-miRNA (pre-miRNA) structure might affect their expression. Previous studies have shown that sequence variation within a pre-miRNA can affect levels of mature miRNA [8, 9]. The density of SNPs within a pre-miRNA has been shown to be lower than the SNP density in the flanking regions [10], and as a result of this constraint SNPs that are present would seem to have arisen fairly recently, meaning that the MAF is low, population-specific and not captured well by GWAS [11, 12]. Any significant associations found in this study, between SNPs with a low MAF and miRNA expression, may be of interest to future studies looking at the effect of rare genetic variation on risk of developing type 2 diabetes.

Materials and methods

Plasmids (pCMV–MIR series) encoding human pre-miR-34a and pre-miR-96, and their flanking regions (at least 284 bp on either side), were purchased from Origene (Rockville, MD, USA). Site-directed mutagenesis was conducted using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA). The correct sequence for each construct was confirmed by Sanger sequencing. For all cell lines, transient transfections were performed using Nucleofector technology (Lonza, Basel, Switzerland) at a density of 1 × 106 cells/transfection. After incubating for 16–24 h, cells were washed in PBS three times, and then total RNA, including miRNA, extracted using the miRVANA miRNA isolation kit (Life Technologies, Carlsbad, CA, USA). For miRNA expression analysis, RNA was reverse transcribed using the miRNA reverse transcription kit (Life Technologies) and miRNA-specific RT primers. Subsequently, miRNA expression levels were determined using miRNA-specific TaqMan assays on the ABI Prism 7900HT real-time PCR platform (Life Technologies). The GeNorm algorithm [13] in RealTime StatMiner software (Integromics, Madrid, Spain) was used to identify the most stable housekeeping genes and thus to normalise miRNA expression levels. The following sets of genes were selected as housekeeping genes: U6, 4.5S and U87 (INS-1); U6, RNU44 and RNU6B (HeLa); U6, snoRNA412 and snoRNA234 (MIN6). For green fluorescent protein (GFP) expression analysis, RNA was first DNase-treated using the Turbo DNA-free kit (Life Technologies), before being reverse transcribed using Superscript III reverse transcriptase (Life Technologies) and random hexamer primers. All qPCR reactions were run on the ABI Prism 7900HT real-time PCR platform (Life Technologies). A custom TaqMan gene expression assay to measure GFP mRNA was designed (Life Technologies) and its ability to robustly determine expression levels validated by standard curve. GFP mRNA levels were normalised using the GeNorm algorithm [13] in RealTime StatMiner software (Integromics, Madrid, Spain) with the following sets of genes selected as housekeeping genes: 18S, ACTB and GUSB (HeLa); Gusb, B2m and Actb (INS-1); B2m, Hmbs and Polr2a (MIN6). Expression of miR-96 and miR-34a was made relative to the expression of the respective miRNA in cells transfected with the major allele of each SNP. To normalise for differences in transfection efficiency, miRNA expression was subsequently normalised to the expression of GFP mRNA in that respective sample. Statistical analysis was determined using Student’s t-test with unequal variances assumed.

Results

In dbSNP version 135, we identified three SNPs within the pre-miRNA sequence of miRNAs important to beta-cell function (Table 1). All SNPs had to have been found in at least one HapMap individual to be included. For a miRNA to be included in our study, we required there to be evidence in the literature for an effect of over-expression or silencing of that miRNA on beta-cell apoptosis or glucose-stimulated insulin secretion. Three SNPs were identified (rs2910164, MAF = 0.38; rs72631823, MAF = 0.001; rs41274239, MAF = 0.002), two of which are located within the terminal loop region of the pre-miRNA and one within the miR* seed sequence. We chose not to study the effects of rs2910164 on miR-146a expression as this is a common SNP, and the effect on miR-146a expression has been previously extensively studied [14-16].
Table 1

miRNAs with a proven role in regulating glucose-stimulated insulin secretion and/or beta-cell apoptosis

Pre-miRNA SNP?Location of SNPReferences
miR-375NoN/A[28]
miR-34aYes—rs72631823Terminal loop[20]
miR-146aYes—rs2910164miR* seed[7]
miR-21NoN/A[7]
miR-96Yes—rs41274239Terminal loop[29]
miR-410NoN/A[30]
miR-200aNoN/A[30]
miR-130aNoN/A[30]
miR-9NoN/A[31]
miR-124NoN/A[29]
miRNAs with a proven role in regulating glucose-stimulated insulin secretion and/or beta-cell apoptosis In MIN6 cells, transfection of plasmids encoding miR-34a and the A (minor) allele of rs72631823 resulted in 2.1-fold higher expression of miR-34a compared to cells transfected with plasmids encoding miR-34a and the G (major) allele of rs72631823 (p = 0.01) (Fig. 1). A similarly increased level of miR-34a expression from plasmids bearing the minor (A) allele of rs72631823 was seen in INS-1 cells (3.8-fold, p = 0.02) and HeLa cells (2.5-fold, p = 0.08) (Fig. 1). Using the Mfold algorithm [17] and web server (http://mfold.rna.albany.edu/), RNA secondary structure predictions support these findings. The terminal loop of the pre-miRNA bearing the A allele of rs72631823 is in a more relaxed, open form than the G allele (Fig. 2). This has been shown to be associated with more efficient Drosha and Dicer processing and consequently higher levels of mature miRNA [18]. In MIN6 cells, transfection of plasmids encoding miR-96 and each allele of rs41274239 resulted in no significant differences in miR-96 expression (data not shown). This was despite a ~eightfold increase in miR-96 expression being measured in cells transfected with plasmids encoding miR-96, and the T (major) allele of rs41274239 compared to cells transfected with empty vector. This finding is consistent with a previous study that did not identify any significant differences in miR-96 expression upon transfection of HeLa cells with miR-96 expression plasmids encoding each allele of rs41274239 [19].
Fig. 1

miRNA expression in cells transfected with plasmids encoding pre-miR-34a and each allele of rs72631823. For each cell line, expression is relative to cells transfected with the pre-miRNA encoding the major allele of rs72631823. Data are presented as mean ± SEM and the results of three independent transfections. Statistical analysis performed using Student’s t-test with unequal variances assumed. *p < 0.05

Fig. 2

Secondary structure of pre-miR-34a for each allele of rs72631823, as predicted by Mfold

miRNA expression in cells transfected with plasmids encoding pre-miR-34a and each allele of rs72631823. For each cell line, expression is relative to cells transfected with the pre-miRNA encoding the major allele of rs72631823. Data are presented as mean ± SEM and the results of three independent transfections. Statistical analysis performed using Student’s t-test with unequal variances assumed. *p < 0.05 Secondary structure of pre-miR-34a for each allele of rs72631823, as predicted by Mfold

Discussion

Two studies have shown that precise control of miR-34a expression in the beta cell is needed to maintain correct beta-cell function. Experiments demonstrated that palmitate and proinflammatory cytokine-induced beta-cell apoptosis result in a threefold to fourfold increase in miR-34a expression and that specifically inhibiting miR-34a activity significantly reduces the stimulus-induced apoptosis [7, 20]. One may conclude from these experiments that miR-34a plays a causal role in beta-cell apoptosis and that small (within one order of magnitude) changes in expression, such as those observed in this study and attributable to allelic effects of rs72631823, may have significant consequences. Our finding of increased miR-34a expression in all three cell lines transfected with the minor versus major allele of rs72631823 suggests that this may not be a tissue-specific phenomenon. Indeed, small deviations in miR-34a expression may have functional consequences in other tissues that play a role in diabetes pathogenesis. Numerous studies have found elevated miR-34a expression in fatty livers of dietary-induced and genetic mouse models of obesity [21-23]. Furthermore, higher miR-34a levels are seen in livers of human individuals with nonalcoholic fatty liver disease [21, 24]. A causal role for miR-34a in metabolic dysregulation within the liver, through regulation of the hepatic response to FGF19, has also been reported [25]. This suggests that increased hepatic miR-34a expression, which may be found in carriers of the rare allele of rs72631823, could promote a more insulin-resistant state and compound the deleterious effects on islet function of higher miR-34a expression. Additionally, the seeming lack of tissue specificity for the effect of rs72631823 on miR-34a expression suggests that results from any future expression quantitative trait loci (eQTL) analysis in an accessible tissue may be justifiably, and with some confidence, extrapolated to more disease relevant, but inaccessible, tissues. The very low MAF and identification exclusively in the Yoruba in Ibadan (YRI) population make eQTL studies for rs72631823, however, a very difficult avenue to pursue. Given recent studies reporting an association of common genetic variation within pre-miRNAs with type 2 diabetes susceptibility [26] and an enrichment of T2D GWAS signals in genes predicted to be targeted by islet-expressed miRNAs [27], the importance of miRNAs to maintenance of beta-cell function cannot be overstated. Indeed, the results of this study may justify analysing a far larger number of SNPs within miRNA genes (perhaps limited to those expressed in the pancreatic islet) and assessing their effects on miRNA expression. Whilst their rarity impedes the finding of significant associations in single-marker tests, methods such as the one presented here can be used to functionally annotate variants for grouping in collapsed/multiple marker tests, which are more likely to uncover significant associations with complex traits, such as type 2 diabetes.
  31 in total

1.  Population differences in microRNA expression and biological implications.

Authors:  R Stephanie Huang; Eric R Gamazon; Dana Ziliak; Yujia Wen; Hae Kyung Im; Wei Zhang; Claudia Wing; Shiwei Duan; Wasim K Bleibel; Nancy J Cox; M Eileen Dolan
Journal:  RNA Biol       Date:  2011-07-01       Impact factor: 4.652

2.  MicroRNAs 103 and 107 regulate insulin sensitivity.

Authors:  Mirko Trajkovski; Jean Hausser; Jürgen Soutschek; Bal Bhat; Akinc Akin; Mihaela Zavolan; Markus H Heim; Markus Stoffel
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

3.  Genetic variants in miRNAs predict bladder cancer risk and recurrence.

Authors:  Meilin Wang; Haiyan Chu; Pu Li; Lin Yuan; Guangbo Fu; Lan Ma; Danni Shi; Dongyan Zhong; Na Tong; Chao Qin; Changjun Yin; Zhengdong Zhang
Journal:  Cancer Res       Date:  2012-07-30       Impact factor: 12.701

4.  MicroRNA genetic variations: association with type 2 diabetes.

Authors:  Cinzia Ciccacci; Davide Di Fusco; Laura Cacciotti; Roberto Morganti; Cinzia D'Amato; Carla Greco; Sara Rufini; Giuseppe Novelli; Federica Sangiuolo; Vincenza Spallone; Paola Borgiani
Journal:  Acta Diabetol       Date:  2013-03-27       Impact factor: 4.280

5.  The terminal loop region controls microRNA processing by Drosha and Dicer.

Authors:  Xiaoxiao Zhang; Yan Zeng
Journal:  Nucleic Acids Res       Date:  2010-07-21       Impact factor: 16.971

6.  Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho.

Authors:  Ting Fu; Sung-E Choi; Dong-Hyun Kim; Sunmi Seok; Kelly M Suino-Powell; H Eric Xu; Jongsook Kim Kemper
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-17       Impact factor: 11.205

Review 7.  MicroRNAs in β-cell biology, insulin resistance, diabetes and its complications.

Authors:  Selene L Fernandez-Valverde; Ryan J Taft; John S Mattick
Journal:  Diabetes       Date:  2011-07       Impact factor: 9.461

8.  The miRNA profile of human pancreatic islets and beta-cells and relationship to type 2 diabetes pathogenesis.

Authors:  Martijn van de Bunt; Kyle J Gaulton; Leopold Parts; Ignasi Moran; Paul R Johnson; Cecilia M Lindgren; Jorge Ferrer; Anna L Gloyn; Mark I McCarthy
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

9.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

10.  Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes.

Authors:  Andrew P Morris; Benjamin F Voight; Tanya M Teslovich; Teresa Ferreira; Ayellet V Segrè; Valgerdur Steinthorsdottir; Rona J Strawbridge; Hassan Khan; Harald Grallert; Anubha Mahajan; Inga Prokopenko; Hyun Min Kang; Christian Dina; Tonu Esko; Ross M Fraser; Stavroula Kanoni; Ashish Kumar; Vasiliki Lagou; Claudia Langenberg; Jian'an Luan; Cecilia M Lindgren; Martina Müller-Nurasyid; Sonali Pechlivanis; N William Rayner; Laura J Scott; Steven Wiltshire; Loic Yengo; Leena Kinnunen; Elizabeth J Rossin; Soumya Raychaudhuri; Andrew D Johnson; Antigone S Dimas; Ruth J F Loos; Sailaja Vedantam; Han Chen; Jose C Florez; Caroline Fox; Ching-Ti Liu; Denis Rybin; David J Couper; Wen Hong L Kao; Man Li; Marilyn C Cornelis; Peter Kraft; Qi Sun; Rob M van Dam; Heather M Stringham; Peter S Chines; Krista Fischer; Pierre Fontanillas; Oddgeir L Holmen; Sarah E Hunt; Anne U Jackson; Augustine Kong; Robert Lawrence; Julia Meyer; John R B Perry; Carl G P Platou; Simon Potter; Emil Rehnberg; Neil Robertson; Suthesh Sivapalaratnam; Alena Stančáková; Kathleen Stirrups; Gudmar Thorleifsson; Emmi Tikkanen; Andrew R Wood; Peter Almgren; Mustafa Atalay; Rafn Benediktsson; Lori L Bonnycastle; Noël Burtt; Jason Carey; Guillaume Charpentier; Andrew T Crenshaw; Alex S F Doney; Mozhgan Dorkhan; Sarah Edkins; Valur Emilsson; Elodie Eury; Tom Forsen; Karl Gertow; Bruna Gigante; George B Grant; Christopher J Groves; Candace Guiducci; Christian Herder; Astradur B Hreidarsson; Jennie Hui; Alan James; Anna Jonsson; Wolfgang Rathmann; Norman Klopp; Jasmina Kravic; Kaarel Krjutškov; Cordelia Langford; Karin Leander; Eero Lindholm; Stéphane Lobbens; Satu Männistö; Ghazala Mirza; Thomas W Mühleisen; Bill Musk; Melissa Parkin; Loukianos Rallidis; Jouko Saramies; Bengt Sennblad; Sonia Shah; Gunnar Sigurðsson; Angela Silveira; Gerald Steinbach; Barbara Thorand; Joseph Trakalo; Fabrizio Veglia; Roman Wennauer; Wendy Winckler; Delilah Zabaneh; Harry Campbell; Cornelia van Duijn; Andre G Uitterlinden; Albert Hofman; Eric Sijbrands; Goncalo R Abecasis; Katharine R Owen; Eleftheria Zeggini; Mieke D Trip; Nita G Forouhi; Ann-Christine Syvänen; Johan G Eriksson; Leena Peltonen; Markus M Nöthen; Beverley Balkau; Colin N A Palmer; Valeriya Lyssenko; Tiinamaija Tuomi; Bo Isomaa; David J Hunter; Lu Qi; Alan R Shuldiner; Michael Roden; Ines Barroso; Tom Wilsgaard; John Beilby; Kees Hovingh; Jackie F Price; James F Wilson; Rainer Rauramaa; Timo A Lakka; Lars Lind; George Dedoussis; Inger Njølstad; Nancy L Pedersen; Kay-Tee Khaw; Nicholas J Wareham; Sirkka M Keinanen-Kiukaanniemi; Timo E Saaristo; Eeva Korpi-Hyövälti; Juha Saltevo; Markku Laakso; Johanna Kuusisto; Andres Metspalu; Francis S Collins; Karen L Mohlke; Richard N Bergman; Jaakko Tuomilehto; Bernhard O Boehm; Christian Gieger; Kristian Hveem; Stephane Cauchi; Philippe Froguel; Damiano Baldassarre; Elena Tremoli; Steve E Humphries; Danish Saleheen; John Danesh; Erik Ingelsson; Samuli Ripatti; Veikko Salomaa; Raimund Erbel; Karl-Heinz Jöckel; Susanne Moebus; Annette Peters; Thomas Illig; Ulf de Faire; Anders Hamsten; Andrew D Morris; Peter J Donnelly; Timothy M Frayling; Andrew T Hattersley; Eric Boerwinkle; Olle Melander; Sekar Kathiresan; Peter M Nilsson; Panos Deloukas; Unnur Thorsteinsdottir; Leif C Groop; Kari Stefansson; Frank Hu; James S Pankow; Josée Dupuis; James B Meigs; David Altshuler; Michael Boehnke; Mark I McCarthy
Journal:  Nat Genet       Date:  2012-08-12       Impact factor: 38.330

View more
  16 in total

1.  Absence of mutation in miR-34a gene in a Chinese longevity population.

Authors:  Huan Wu; Yong-Han He; Tian-Rui Xu; Qing-Peng Kong
Journal:  Dongwuxue Yanjiu       Date:  2015-03-18

2.  Effects of TRPM7/miR-34a Gene Silencing on Spatial Cognitive Function and Hippocampal Neurogenesis in Mice with Type 1 Diabetes Mellitus.

Authors:  Qing-Jiu Zhang; Jie Li; Song-Yun Zhang
Journal:  Mol Neurobiol       Date:  2017-02-09       Impact factor: 5.590

Review 3.  Role of miRNAs in the pathogenesis and susceptibility of diabetes mellitus.

Authors:  Naoko Hashimoto; Tomoaki Tanaka
Journal:  J Hum Genet       Date:  2016-12-08       Impact factor: 3.172

Review 4.  Beyond the Protein-Coding Sequence: Noncoding RNAs in the Pathogenesis of Type 2 Diabetes.

Authors:  Johanna K DiStefano
Journal:  Rev Diabet Stud       Date:  2016-01-28

5.  Association study of a common genetic variant in pre-miR-1596 with chicken performance traits.

Authors:  Hong Li; Yadong Tian; Guirong Sun; Xiaojun Liu; Ruirui Jiang; Ruili Han; Guoxi Li; Xiangtao Kang
Journal:  Mol Biol Rep       Date:  2014-07-20       Impact factor: 2.316

6.  The role of miRNA-34a as a prognostic biomarker for cirrhotic patients with portal hypertension receiving TIPS.

Authors:  Christian Jansen; Hannah Eischeid; Jan Goertzen; Robert Schierwagen; Evrim Anadol; Christian P Strassburg; Tilman Sauerbruch; Margarete Odenthal; Jonel Trebicka
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

7.  Role of microRNAs in the age-associated decline of pancreatic beta cell function in rat islets.

Authors:  Ksenia Tugay; Claudiane Guay; Ana C Marques; Florent Allagnat; Jonathan M Locke; Lorna W Harries; Guy A Rutter; Romano Regazzi
Journal:  Diabetologia       Date:  2016-01       Impact factor: 10.122

8.  Downregulation of Bcl-2 expression by miR-34a mediates palmitate-induced Min6 cells apoptosis.

Authors:  Xiaojie Lin; Hongyu Guan; Zhimin Huang; Juan Liu; Hai Li; Guohong Wei; Xiaopei Cao; Yanbing Li
Journal:  J Diabetes Res       Date:  2014-04-14       Impact factor: 4.011

9.  Identification of miR-34a-target interactions by a combined network based and experimental approach.

Authors:  Martin Hart; Stefanie Rheinheimer; Petra Leidinger; Christina Backes; Jennifer Menegatti; Tobias Fehlmann; Friedrich Grässer; Andreas Keller; Eckart Meese
Journal:  Oncotarget       Date:  2016-06-07

10.  T2DiACoD: A Gene Atlas of Type 2 Diabetes Mellitus Associated Complex Disorders.

Authors:  Jyoti Rani; Inna Mittal; Atreyi Pramanik; Namita Singh; Namita Dube; Smriti Sharma; Bhanwar Lal Puniya; Muthukurussi Varieth Raghunandanan; Ahmed Mobeen; Srinivasan Ramachandran
Journal:  Sci Rep       Date:  2017-07-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.